AAIPharma Acquires CRO in Brazil

AAIPharma, Inc. completed the acquisition of Instituto de Pesquisa Clinica de Sao Paulo, Ltd. (IPCSP), a CRO in Brazil. The acquisition of IPCSP adds to the company’s existing operations in South America, in Argentina and Peru.

“Expanding AAIPharma’s presence in Brazil is important for our customers who want access to the substantial South American patient populations,” said Ludo Reynders, Ph.D., AAIPharma’s president and chief executive officer. “Brazil is a highly populous gateway to South America which is a key region for the continued growth of clinical development worldwide. With the highly trained clinical research professionals from IPCSP and their network of physicians, AAIPharma can offer pharmaceutical and biotech customers broader reach for their large multinational trials.”

IPCSP has experience managing Phase I-IV trials across a wide range of therapeutic areas. The company’s service offerings include medical and clinical monitoring, project management, regulatory affairs, pharmacovigilance, clinical supplies, drug importation, drug storage, drug distribution, and sample exportation.

“AAIPharma’s global presence and experience will create significant value for our customers,” said Andrea Saud Martinez, Pharm.D., M.Sc., IPCSP founder and chief executive officer, who will become general manager of AAIPharma’s South American Operations. “We look forward to enhancing our breadth and depth of services, and remain focused on continued growth throughout South America.”

The terms of the transaction were not disclosed.